Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

cacy or may not be accepted by the market for other reasons; the Company's ability to expand its product offerings through internal development or acquisition; disruption at any of the Company's manufacturing facilities; the general uncertainty related to seeking regulatory approvals for the Company's products, particularly in the United States; potential claims of third parties that the Company's products infringe their intellectual property rights; and the risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by any subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Financial Statements

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands)

March 31, 2008 December 31, 2007

(unaudited)

Assets

Current assets:

Cash and cash equivalents $5,444 $6,691

Marketable securities 12,358 16,198

Accounts receivable, net 7,166 7
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... botanical and plant-derived compounds. BCC Research reveals in its new report that ... this market defines the category and generates the most market demand. , ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... Anderson , president and chief executive officer, will present ... September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may be ... will be available shortly after conclusion of the presentation ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to aid high-risk surgeries. From vital sign monitoring in ICU to 3D skull ... enables surgeon to make real-time clinical decisions with simultaneous access to high precision ...
(Date:9/2/2015)... England (PRWEB) , ... September 02, 2015 , ... ... drug discovery and life science research, today unveiled Genedata Screener ® version ... for all in-vitro screening brings to market a rich set of new capabilities. ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... WILMINGTON, Delaware, November 3 The new market ... (2009 - 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) ... market. It identifies and analyzes,the main market drivers, ... and applications submarkets in different,geographic regions. , ...
... ... key hire. Cindy Larkin has been hired as Director of Client Services. Cindy ... , ... (Vocus) November 3, 2009 -- Leading medical device and life sciences software engineering consulting ...
... of Delaware has won a $4.4 million grant ... Projects Agency (ARPA-E) to lead a multidisciplinary, multi-institutional ... high-performance permanent magnets. Stronger magnets are essential ... information technology, and communications systems in the 21st-century, ...
Cached Biology Technology:MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2UD wins $4.4 million to develop next-generation magnets 2
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... release is available in German . ... have now developed a new strategy for the formation ... have thus been able to fuse the specific biological ... properties of plastics. Polymer-protein hybrid materials may be of ...
... with a particularly aggressive form of breast cancer seem ... combined anthracycline and taxane chemotherapy regimen before surgery, together ... results from the largest multi-centre trial to investigate this ... Breast Cancer Conference (EBCC-6) in Berlin today (Friday) that ...
... Alliance for Lupus Research (ALR) recently announced it will award ... ALR is very proud to announce, during National Minority Health ... has funded more than 100 research projects, and committed more ... says ALR President Barbara Boyts. For a full list of ...
Cached Biology News:Green gel 2Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer 2The Alliance for Lupus Research announces 2008 grantees 2
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... Protein Kit is a simple and convenient method ... The kit has been optimized for use with ... used for any fungus species that is susceptible ... procedure effectively generates spheroplasts of yeast cells that ...
... is a pleiotropic cytokine produced by activated ... OSM inhibits the growth of some tumour ... muscle and Kaposis sarcoma cell proliferation, cytokine ... lipoprotein receptor expression on hepatoma cells. Mouse ...
Biology Products: